Synthorx (THOR) began trading on the Nasdaq on 7 December 2018

Update Dec 9, 2019:  Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 billion

------

The biopharmaceutical company Synthorx designs proteins for targeted therapeutic modulation of tumors and autoimmune disorders.

Synthorx opened for trading at $15.40 after pricing IPO at $11.

The company issued 9.1 million shares

Moderna (MRNA) began trading on the Nasdaq on 7 December 2018

Moderna, Inc. is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA (mRNA). The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.
The pharma is shaping its mRNA platform into prophylactic and cancer vaccines, as well as immuno-oncology, regenerative and systemic therapeutics.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.

Sector: Healthcare
Industry: Biotechnology
Headquarters: Cambridge, Massachusetts
Number of employees: ~700
Founded: 2010
http://www.modernatx.com

Offer size: $604 million; 21.7 million shares 

Inspire Medical Systems (INSP) prices 2.5 mln shares at $40.00 per share

• Inspire Medical Systems announces pricing of previously announced offering of 2.5 mln shares of its common stock at a public offering price of $40.00 per share